You are here
- Home
- Media
- Press releases
- 2001
ASTRAZENECA INVESTS $10M IN BANGALORE LABORATORIES
- Reference code :
- wf387
- Published date :
-
25 April 2001
- Expired date :
-
10 September 2028
AstraZeneca PLC today announced plans for investment in India to create a centre of excellence at its facility in Bangalore for the discovery and development of new medicines of importance to the developing world.
The research centre, which aims to recruit additional world class scientists, will focus principally on finding a new treatment for tuberculosis, a disease which currently affects two million people every year in India and 16 million people worldwide, mostly in the developing world (WHO Report 2000).
The investment programme will include $10 million to create new research laboratories in Bangalore, and $5 million in 2001 to support research activities.
"With no new drugs for TB in the past 40 years, our remit will be to improve understanding of the basic physiology of the TB pathogen so that we can provide both a reliable diagnostic test and a more effective cure for the disease, " said Dr Claes Wilhelmsson, Executive Director, R&D at AstraZeneca. "These new laboratories will form an integral part of our research into infectious diseases and, together with academic collaborations, AstraZeneca in Bangalore will become a leading centre of excellence for TB research."
Dr Barry Furr, Chief Scientist and Head of the Project Evaluation Group at AstraZeneca, has been appointed to lead the laboratory which currently houses 65 scientists, and plans to recruit more scientists over the next five years from India and overseas.
The research programme, which will involve collaborations with academia and shared expertise with AstraZeneca’s genomics and infection research centres in Boston, USA, and in Cheshire, UK, will have three components:
Dr Stewart Cole, Head of the Unité de Génétique Moléculaire Bactérienne at The Institut Pasteur in Paris, who pioneered the work on the sequencing of the TB genome, is a member of the scientific advisory board for the new research centre said: "AstraZeneca is the only pharmaceutical company to recognise this area of medical need with a research programme in India dedicated to TB, and I am delighted to be able to work with them on this important project."
Dr Tanjore Balganesh, Head of Research at the Bangalore laboratory, said: "Bangalore is the academic centre of India and we are very excited to have this opportunity to attract top class scientists to work with us on this programme."
Further enquires to:
|
Steve Brown +44 (0)20 7304 5033 Chris Major +44 (0)20 7304 5028 Leslie Wheeler +44 (0) 1625 519 790 Kumud Sampath (Bangalore) +91 80 3340372 |
Note to News Editors: |
|
|
|
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At Nov 21, 2009 6:45 AM GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
